港股異動 | 中國飛鶴(6186.HK)一度漲超7% 發佈澄清公告 回擊Blue Orca Capital沽空指控
格隆匯7月9日丨昨日午後直線拉昇並收漲7.21%的中國飛鶴(6186.HK)今日一度漲超7%,現漲幅回落至3.77%,報17.6港元,暫成交5265萬港元,最新總市值1572億港元。中國飛鶴今晨發佈澄清公告,董事會注意到Blue Orca Capital於2020年7月8日刊發了一份報告,該報告載有(其中包括)對公司財務表現的指控。董事會僅此澄清,該報告中的相關指控毫無事實根據或為失實陳述。昨日午間公司亦發公告稱,預期集團截至6月30日止六個月的收入將同比增超40%,該等增長主要得益於高端嬰幼兒配方奶粉銷量的大幅增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.